Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:BCAX NASDAQ:XNCR NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$10.98-0.7%$8.98$4.93▼$14.44$937.88M0.721.19 million shs762,981 shsBCAXBicara Therapeutics$10.93-6.2%$10.81$7.80▼$28.09$596.08MN/A590,978 shs345,263 shsXNCRXencor$8.97-1.1%$8.50$7.16▼$27.24$638.40M0.85687,519 shs417,365 shsYMABY-mAbs Therapeutics$4.31-0.2%$4.52$3.55▼$16.11$195.17M0.51293,920 shs157,975 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-1.17%+21.59%+22.68%+85.47%BCAXBicara Therapeutics0.00%+12.56%+15.91%-10.12%+1,092,999,900.00%XNCRXencor0.00%+1.59%+7.30%-7.53%-54.83%YMABY-mAbs Therapeutics0.00%-1.15%-6.91%-8.10%-65.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.9108 of 5 stars3.71.00.04.72.50.80.6BCAXBicara Therapeutics2.005 of 5 stars3.50.00.00.02.10.80.6XNCRXencor4.1173 of 5 stars3.45.00.03.90.00.81.3YMABY-mAbs Therapeutics3.6743 of 5 stars4.45.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00300.73% UpsideBCAXBicara Therapeutics 3.00Buy$31.86191.48% UpsideXNCRXencor 2.75Moderate Buy$28.00212.15% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$15.60261.95% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, BCAX, XNCR, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.005/28/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$21.00 ➝ $18.005/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/19/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/14/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.005/14/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/8/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.004/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.004/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ABCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/AXNCRXencor$110.49M5.78N/AN/A$9.63 per share0.93YMABY-mAbs Therapeutics$87.68M2.23N/AN/A$2.05 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)BCAXBicara Therapeutics-$68MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)XNCRXencor-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)Latest YMAB, BCAX, XNCR, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54N/AN/AN/AN/AN/A8/11/2025Q2 2025YMABY-mAbs Therapeutics-$0.27N/AN/AN/A$18.40 millionN/A8/5/2025Q3 2025AVXLAnavex Life Sciences-$0.13N/AN/AN/AN/AN/A8/4/2025Q2 2025XNCRXencor-$0.78N/AN/AN/A$22.59 millionN/A5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A6.746.74BCAXBicara TherapeuticsN/A24.6224.62XNCRXencor0.165.895.89YMABY-mAbs TherapeuticsN/A4.774.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%BCAXBicara TherapeuticsN/AXNCRXencorN/AYMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%BCAXBicara Therapeutics15.50%XNCRXencor4.76%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.42 million75.68 millionOptionableBCAXBicara Therapeutics3254.54 million46.08 millionN/AXNCRXencor28071.17 million67.78 millionOptionableYMABY-mAbs Therapeutics15045.28 million36.36 millionOptionableYMAB, BCAX, XNCR, and AVXL HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 4, 2025 | marketbeat.comYMAB Y-mAbs Therapeutics, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comY mAbs Therapeutics News (YMAB) - Investing.comJune 26, 2025 | investing.comWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn RateJune 11, 2025 | finance.yahoo.comY-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineMay 28, 2025 | globenewswire.comY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26, 2025 | insidermonkey.comY-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research MeetingMay 26, 2025 | quiverquant.comQY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26, 2025 | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025May 13, 2025 | globenewswire.comY-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | globenewswire.comY-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)May 7, 2025 | globenewswire.comWhy Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%May 6, 2025 | aaii.comAY-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025May 6, 2025 | globenewswire.comEarnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to DeclineApril 29, 2025 | zacks.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, BCAX, XNCR, and AVXL Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$10.98 -0.08 (-0.72%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.01 +0.03 (+0.27%) As of 07/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Bicara Therapeutics NASDAQ:BCAX$10.93 -0.72 (-6.18%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$10.90 -0.03 (-0.27%) As of 07/18/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Xencor NASDAQ:XNCR$8.97 -0.10 (-1.10%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.97 0.00 (0.00%) As of 07/18/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Y-mAbs Therapeutics NASDAQ:YMAB$4.31 -0.01 (-0.23%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.35 +0.04 (+0.93%) As of 07/18/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.